

**Table 3 Covariates of survival of cases diagnosed as HIV-positive with a diagnosis of AIDS, applying the Weibull model, 1997–2003**

Covariate	Hazard ratio	95% CI	P-value
<b>Age (years)</b>			
< 20	0.97	0.39–2.44	0.950
20–24	1.59	0.88–2.89	0.127
25–29	1.43	1.11–1.86	0.007
30–34	1.01	0.83–1.24	0.886
35–39	1.00	–	–
40–44	1.04	0.86–1.23	0.728
45–49	1.01	0.83–1.22	0.932
50–54	1.22	1.00–1.50	0.055
55–59	1.33	1.05–1.70	0.019
60+	2.08	1.62–2.49	< 0.001
<b>Reported HIV exposure</b>			
Male: homosexual	1.00	–	–
Male: heterosexual	0.81	0.62–1.04	0.103
Female: heterosexual	1.01	0.73–1.40	0.936
Male: IV drug user	1.36	1.01–1.82	0.043
Female: IV drug user	1.07	0.66–1.74	0.770
Male: blood transfused	0.96	0.60–1.54	0.874
Female: blood transfused	1.38	0.71–2.67	0.342
Male: other exposures <sup>a</sup>	1.11	0.88–1.41	0.368
Female: other exposures <sup>b</sup>	0.71	0.41–1.22	0.211
<b>CD4 cell count(cells/µL)</b>			
< 20	1.00	–	–
20–50	0.91	0.75–1.09	0.291
50–100	0.87	0.72–1.05	0.149
100–200	0.83	0.69–1.00	0.056
≥ 200	0.58	0.48–0.71	< 0.001
Unknown	0.56	0.45–0.70	< 0.001
<b>AIDS-defining illness</b>			
<i>Pneumocystis jiroveci</i>	1.00	–	–
Kaposi sarcoma	1.15	0.93–1.42	0.192
Non-Hodgkin lymphoma	2.51	1.95–3.22	< 0.001
Other infections	1.15	0.97–1.35	0.089
CNS conditions	1.26	1.04–1.52	0.019

Wasting syndrome	1.16	0.92–1.47	0.214
Other one or more illnesses	1.36	1.13–1.64	0.001
<b><i>Antiretroviral therapy</i></b>			
Mono/double	33.03	0.0007–160	0.525
HAART	2.65	0.84–8.32	0.094

<sup>a</sup>From high prevalence country, no sexual contact and unknown exposure; <sup>b</sup>From high prevalence country, no sexual contact, vertical transmission and unknown exposure.  
 CI = confidence interval; IV = intravenous; CNS = central nervous system; HAART = highly active antiretroviral therapy.